Fcγ受体多态性与HER2阳性乳腺癌患者对曲妥珠单抗的反应：远非预测价值？
FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?
作者信息
Botticelli Andrea, Mazzuca Federica, Borro Marina, Mazzotti Eva, La Torre Marco, Bonifacino Adriana, Ciabatta Francesca Romana, Gentile Giovanna, Maddalena Chiara, Simmaco Maurizio, Marchetti Paolo
机构信息
Department of Molecular and Clinical Medicine, "Sapienza" University of Rome, Sant'Andrea Hospital, Rome, Italy.
Department of Neurosciences, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome - Advanced Molecular Diagnostics Unit (DiMA), Sant'Andrea Hospital, Rome, Italy.
出版信息
World J Oncol. 2015 Oct;6(5):437-440. doi: 10.14740/wjon934w. Epub 2015 Oct 26.
BACKGROUND
The aim of the study was to validate the association between the Arg166His polymorphisms of the Fc immunoglobulin receptor 2A (FCGR2A) and the Val212Phe of FCGR3A and pathological clinical response (pCR) to trastuzumab in HER2-positive breast cancer patients.
METHODS
Polymorphisms were characterized by pyrosequencing in 26 patients with ductal histotype breast cancer in a neoadjuvant setting and genotype association with pCR was analyzed.
RESULTS
No association was found between the FCGR3A Val212Phe polymorphisms and pCR. In contrast, the FCGR2A GG genotype (Arg allele) was found to be positively associated with pCR (P = 0.012).
CONCLUSIONS
Our results do not support previously reported data on the effect of polymorphisms in immunoglobulin Fc receptors upon response to trastuzumab therapy.
背景
本研究旨在验证Fc免疫球蛋白受体2A（FCGR2A）的Arg166His多态性和FCGR3A的Val212Phe多态性与HER2阳性乳腺癌患者对曲妥珠单抗的病理临床反应（pCR）之间的关联。
方法
采用焦磷酸测序法对26例新辅助治疗的导管组织型乳腺癌患者的多态性进行特征分析，并分析基因型与pCR的相关性。
结果
未发现FCGR3A Val212Phe多态性与pCR之间存在关联。相反，发现FCGR2A GG基因型（Arg等位基因）与pCR呈正相关（P = 0.012）。
结论
我们的结果不支持先前报道的关于免疫球蛋白Fc受体多态性对曲妥珠单抗治疗反应影响的数据。
Zotero 插件